Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies

被引:70
作者
Armbruster, Nicole [1 ]
Jasny, Edith [2 ]
Petsch, Benjamin [3 ]
机构
[1] CureVac AG, Scientist Prophylact Vaccines Nonclin Dev, Paul Ehrlich Str 15, D-72076 Tubingen, Germany
[2] CureVac AG, Senior Scientist Prophylact Vaccines Nonclin Dev, Paul Ehrlich Str 15, D-72076 Tubingen, Germany
[3] CureVac AG, Senior Director Prophylact Vaccines Res, Paul Ehrlich Str 15, D-72076 Tubingen, Germany
关键词
rabies vaccines; mRNA vaccines; lipid nanoparticles; EFFICACY; IMMUNOGENICITY; PROPHYLAXIS; INNATE;
D O I
10.3390/vaccines7040132
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There is a global need for effective and affordable rabies vaccines, which is unmet by current vaccines due to limitations in their production capacities, required administration schedules, storage requirements, and cost. Many different experimental approaches previously used for bacterial and viral vaccines have been applied to rabies, but with variable success. One of the most promising new concepts is the use of messenger RNA (mRNA) in encoding the main rabies virus antigen, the envelope glycoprotein (RABV-G). CureVac has applied their proprietary technology platform for the production of mRNA to this problem, resulting in the rabies vaccine candidate CV7201. Following preclinical studies in mice and pigs showing that CV7201 could induce neutralizing immune responses that protected against rabies virus, different dosages and routes of administration of CV7201 were tested in a phase 1 human study. This clinical study proved that mRNA vaccination was safe and had an acceptable reactogenicity profile, but immune responses depended on the mode of administration, and they did not unequivocally support CV7201 for further development as a prophylactic vaccine with this particular formulation. Further, preclinical studies using RABV-G mRNA encapsulated in lipid nanoparticles (LNPs) showed an improved response in both mice and nonhuman primates, and these encouraging results are currently being followed up in clinical studies in humans. This review summarizes the recent advances in mRNA vaccines against rabies.
引用
收藏
页数:12
相关论文
共 44 条
[1]   Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].
Alberer, Martin ;
Gnad-Vogt, Ulrike ;
Hong, Henoch Sangjoon ;
Mehr, Keyvan Tadjalli ;
Backert, Linus ;
Finak, Greg ;
Gottardo, Raphael ;
Bica, Mihai Alexandru ;
Garofano, Aurelio ;
Koch, Sven Dominik ;
Fotin-Mleczek, Mariola ;
Hoerr, Ingmar ;
Clemens, Ralf ;
von Sonnenburg, Frank .
LANCET, 2017, 390 (10101) :1511-1520
[2]  
[Anonymous], 2016, Wkly Epidemiol Rec, V91, P13
[3]  
[Anonymous], GUID RAB PRE POST PR
[4]   Rabies vaccine development by expression of recombinant viral glycoprotein [J].
Astray, Renato Mancini ;
Calil Jorge, Soraia Attie ;
Pereira, Carlos Augusto .
ARCHIVES OF VIROLOGY, 2017, 162 (02) :323-332
[5]  
BAER GM, 1988, REV INFECT DIS, V10, pS739
[6]   A NEW INACTIVATED TISSUE-CULTURE RABIES VACCINE FOR USE IN MAN EVALUATION OF PCEC-VACCINE BY LABORATORY TESTS [J].
BARTH, R ;
GRUSCHKAU, H ;
BIJOK, U ;
HILFENHAUS, J ;
HINZ, J ;
MILCKE, L ;
MOSER, H ;
JAEGER, O ;
RONNEBERGER, H ;
WEINMANN, E .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1984, 12 (01) :29-&
[7]   Human rabies post exposure prophylaxis at the Pasteur Institute of Dakar, Senegal: trends and risk factors [J].
Diallo, Mamadou Korka ;
Diallo, Alpha Oumar ;
Dicko, Anta ;
Richard, Vincent ;
Espie, Emmanuelle .
BMC INFECTIOUS DISEASES, 2019, 19 (1)
[8]   Chemokines: Key players in innate and adaptive immunity [J].
Esche, C ;
Stellato, C ;
Beck, LA .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (04) :615-628
[9]   New human rabies vaccines in the pipeline [J].
Fooks, Anthony R. ;
Banyard, Ashley C. ;
Ertl, Hildegund C. J. .
VACCINE, 2019, 37 :A140-A145
[10]   Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity [J].
Fotin-Mleczek, Mariola ;
Duchardt, Katharina M. ;
Lorenz, Christina ;
Pfeiffer, Regina ;
Ojkic-Zrna, Sanja ;
Probst, Jochen ;
Kallen, Karl-Josef .
JOURNAL OF IMMUNOTHERAPY, 2011, 34 (01) :1-15